A patient with severe renal impairment (eGFR 15 mL/min/1.73m²) requires a contrast-enhanced CT scan. Which of the following contrast agents carries the lowest risk of contrast-induced nephropathy?

Explanation

## Contrast Agent Selection in Renal Impairment **Key Point:** In patients with severe renal disease, iso-osmolality contrast media (IOCM) offer the lowest risk of contrast-induced nephropathy (CIN) because they do not create osmotic gradients that worsen renal perfusion. ### Risk Stratification by Agent Type in CKD | Agent Type | Osmolality | CIN Risk in CKD | Mechanism of Injury | |------------|------------|-----------------|--------------------| | Ionic monomer (HOCM) | 1500–2400 | Highest | Osmotic diuresis, tubular toxicity, vasoconstriction | | Non-ionic monomer (LOCM) | 600–850 | Moderate | Residual osmotic effect, direct tubular toxicity | | Non-ionic dimer (IOCM) | ~290 | Lowest | Iso-osmolal—no osmotic gradient | | Gadolinium | Variable | Nephrogenic systemic fibrosis (NSF) risk | Contraindicated in eGFR <30 | **High-Yield:** Iodixanol (Visipaque®) is the only iso-osmolality iodinated contrast agent approved for IV use. Multiple randomized trials (PRESERVE trial, PRESERVE-CKD) have demonstrated that IOCM reduces CIN risk compared to LOCM in high-risk patients, though the absolute benefit is modest (~1–2% reduction). **Clinical Pearl:** Current guidelines recommend LOCM or IOCM for all patients with eGFR <60 mL/min/1.73m². IOCM is preferred in eGFR 15–30 mL/min/1.73m² or when multiple risk factors for CIN are present (diabetes, dehydration, advanced age). **Mnemonic:** **IOCM = Iso-osmolal = Safest in CKD** (osmolality = plasma osmolality, no osmotic stress). ### Why Iodixanol is Superior in Severe Renal Disease - Osmolality ~290 mOsm/kg (equal to plasma) - No osmotic gradient → no osmotic diuresis - No tubular fluid hypertonicity → reduced direct tubular toxicity - Maintains renal perfusion pressure better than LOCM - Reduces CIN incidence by 1–2% vs. LOCM in eGFR <30